All News

While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.

The study provides evidence of survival benefits among patients with Duchenne muscular dystrophy (DMD) receiving eteplirsen compared with the natural history of the condition.

JAMA used a case report of rhino-orbital-cerebral mucormycosis in a patient with uncontrolled diabetes to demonstrate correct and incorrect treatment choices.

Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.

A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.

Men who have sex with men (MSM) who are HIV-negative reported interest in an injectable pre-exposure prophylaxis (PrEP) that lasted longer than the daily pill, regardless of cost or coverage.

Researchers addressed the impact of long-term coverage of telemedicine, following concerns that it will increase spending and hurt health care quality.

A large cohort study demonstrated the validity and reliability of single-channel electro-oculography (EOG) for sleep-stage classification.

Stacey Ehrenberg, MD, discusses the lacking data and potential implications of using glucagon-like peptide-1 (GLP-1) receptor agonists during pregnancy for patients with diabetes and/or obesity.

The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.

In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, discusses various surveys deployed within Advocate Health to promote organizational well-being.

New guidance on managing desmoid fibromatosis recommends a more conservative approach, encompassing the patient perspective, active surveillance, tumor location, and risk-benefit assessment.

Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.

For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.

In addition to sharing research related to disparities and inequities in the cardiometabolic space, Rashon Lane, PhD, MA, Sutter Health, discussed “how we might need to think differently about how we are intervening on disparities.”

A new study found that dentists were lacking in experience when it came to dental aspects of HIV infection.

This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.

Melatonin showed no benefit for cancer-related fatigue or other symptoms in women with early-stage breast cancer receiving radiotherapy treatment.

Diana Isaacs, PharmD, chair of a recent Institute for Value-Based Medicine® event hosted in conjunction with Cleveland Clinic, details the up-and-coming therapies impacting the scope of treatment in diabetes, obesity, and cardiometabolic health, as well as their associated challenges.

The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.

Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).

Patients with chronic obstructive pulmonary disease (COPD) and muscle loss phenotype (MLP) have an elevated risk of all-cause or COPD-related mortality.

EVIdeNCE study data, from real-world practice, confirm the efficacy and safety that ibrutinib previously demonstrated in clinical trials involving patients with CLL, according to the study authors.

Binod Dhakal, MD, associate professor, Medical College of Wisconsin, is lead investigator of the CARTITUDE-4 study, from which data were used by the FDA to approve ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 1 prior line of therapy.

Robert Zimmerman, MD, discussed the adverse side effects associated with glucagon-like peptide-1 (GLP1) and multi-agonist therapies, as well as explored the challenges in developing these interventions.

New data show that survival in patients living with postoperative colorectal cancer (CRC) could be predicted using a nomogram model.

New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.